BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 1, 2019
View Archived Issues
Mutation in MIR140 gene tied to skeletal dysplasia
Read More
Theranexus presents preliminary results of phase II study of THN-102 on patients with narcolepsy
Read More
Shionogi and Nagasaki University to collaborate in the field of infectious diseases
Read More
Hinova Pharmaceuticals describes new antitubercular compounds
Read More
Hiroshima University and collaborators present new PPIase Pin1 inhibitors
Read More
Technique boosts single-cell level grasp of DNA replication
Read More
ViiV Healthcare enters collaboration with Radboud University Medical Center
Read More
New STAT3 inhibitors discovered at King's College London
Read More
Amgen presents promising preclinical data for AMG-160
Read More
Teligene patents high affinity nerve growth factor receptor inhibitors
Read More
MDI-2268 shows safety and efficacy in murine model of deep vein thrombosis
Read More
Bromodomain-containing protein 4 inhibitors identified at Zhejiang Hisun Pharmaceutical
Read More
FDA allows initiation of phase I study of CT-044
Read More
AbCellera enters antibody discovery collaboration in neurology with Denali
Read More
Takeda Pharmaceutical presents the discovery of novel potent and selective Nav1.1 activator
Read More
Single-nulceotide polymorphism in ADGRL3 gene found predictor of substance use disorder
Read More
Azetidine optimization leads to clinical candidate JTE-952 for rheumatoid arthritis
Read More
Abpro and NJCTTQ partner to develop bispecific antibody therapies in immuno-oncology
Read More
Apellis enters collaboration with SFJ Pharmaceuticals for APL-2 in hematologic indications
Read More
Researchers find biomarkers associated with risk of GvHD
Read More
Minoryx receives Spanish clearance to begin phase II trial of MIN-102 in Friedreich's ataxia
Read More
Topivert Pharma initiates phase II/III study of TOP-1630 in dry eye syndrome
Read More
Armed oncolytic adenovirus targets tumor stroma to enhance viral spread
Read More
Phase III FORWARD I trial of mirvetuximab soravtansine does not meet primary endpoint
Read More
FDA approves Herceptin Hylecta for HER2-positive breast cancer
Read More